Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT04077463 2026-04-13

Chrysalis-2

Phase 1 Active not recruiting

701 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-04-13

PAPILLON

Phase 3 Active not recruiting

308 enrolled 12 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05388669 2026-04-13

PALOMA-3

Phase 3 Active not recruiting

418 enrolled 16 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05488314 2026-04-13

METalmark

Phase 1/2 Active not recruiting

57 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05498428 2026-04-13

PALOMA-2

Phase 2 Recruiting

520 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05663866 2026-04-13

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Phase 2 Active not recruiting

68 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06120140 2026-04-13

COCOON

Phase 2 Recruiting

300 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06532032 2026-04-13

swalloWTail

Phase 1/2 Active not recruiting

12 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06667076 2026-04-13

COPERNICUS

Phase 2 Recruiting

480 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07227025 2026-04-13

KaRAnaSa

Phase 1/2 Recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05801029 2026-03-20

OSTARA

Phase 2 Active not recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05908734 2026-03-13

PolyDamas

Phase 1/2 Active not recruiting

71 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-02-05

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 3 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-02-04

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 3 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04599712 2025-06-13

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06816992 2025-03-20

ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC

Phase 1 Recruiting

76 enrolled

Other solid neoplasmThoracic

Solid Tumors

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

5 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Clinical Trials

CHRYSALIS

Chrysalis-2

PAPILLON

PALOMA-3

METalmark

PALOMA-2

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

COCOON

swalloWTail

COPERNICUS

KaRAnaSa

OSTARA

PolyDamas

MARIPOSA-2

MARIPOSA

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors